Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit
VX-787 的临床前活性，VX-787 是一流口服生物利用度高的流感病毒聚合酶 PB2 亚基抑制剂
期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.1
doi:10.1128/AAC.04623-14
Randal A Byrn, Steven M Jones, Hamilton B Bennett, Chris Bral, Michael P Clark, Marc D Jacobs, Ann D Kwong, Mark W Ledeboer, Joshua R Leeman, Colleen F McNeil, Mark A Murcko, Azin Nezami, Emanuele Perola, Rene Rijnbrand, Kumkum Saxena, Alice W Tsai, Yi Zhou, Paul S Charifson
